OBJECTIVE: Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes. DESIGN: Cross-sectional study at baseline for a randomized controlled trial. METHODS: HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 T-cell count, interleukin-6, and alcohol use severity. RESULTS: The sample of 84 virally suppressed MSM had a median CD4 T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05). CONCLUSIONS:Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.
RCT Entities:
OBJECTIVE: Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes. DESIGN: Cross-sectional study at baseline for a randomized controlled trial. METHODS: HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 T-cell count, interleukin-6, and alcohol use severity. RESULTS: The sample of 84 virally suppressed MSM had a median CD4 T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05). CONCLUSIONS: Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.
Authors: Michael R Irwin; Luis Olmos; Minge Wang; Edwin M Valladares; Sarosh J Motivala; Tim Fong; Tom Newton; Anthony Butch; Richard Olmstead; Steve W Cole Journal: J Pharmacol Exp Ther Date: 2006-10-26 Impact factor: 4.030
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Christine D Palmer; Julia Tomassilli; Michael Sirignano; Marisol Romero-Tejeda; Kelly B Arnold; Denise Che; Douglas A Lauffenburger; Stephanie Jost; Todd Allen; Kenneth H Mayer; Marcus Altfeld Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: Marta Massanella; Sara Gianella; Rachel Schrier; Jennifer M Dan; Josué Pérez-Santiago; Michelli F Oliveira; Douglas D Richman; Susan J Little; Constance A Benson; Eric S Daar; Michael P Dube; Richard H Haubrich; Davey M Smith; Sheldon R Morris Journal: Sci Rep Date: 2015-08-24 Impact factor: 4.379
Authors: Jared Lee; Ji-Young Lee; Christina S Meade; Michael Cohn; Antonio Chahine; Samantha E Dilworth; Jessica F Magidson; Hetta Gouse; Dietmar Fuchs; Adam W Carrico Journal: J Neurovirol Date: 2020-07-29 Impact factor: 2.643
Authors: Adam W Carrico; Annesa Flentje; Kord Kober; Sulggi Lee; Peter Hunt; Elise D Riley; Steven Shoptaw; Elena Flowers; Samantha E Dilworth; Savita Pahwa; Bradley E Aouizerat Journal: Brain Behav Immun Date: 2018-04-18 Impact factor: 7.217
Authors: Olorunleke Oni; Tiffany R Glynn; Michael H Antoni; Danita Jemison; Allan Rodriguez; Mark Sharkey; Jessica Salinas; Mario Stevenson; Adam W Carrico Journal: Int J Behav Med Date: 2019-10
Authors: Delaram Ghanooni; Adam W Carrico; Renessa Williams; Tiffany R Glynn; Judith T Moskowitz; Savita Pahwa; Suresh Pallikkuth; Margaret E Roach; Samantha Dilworth; Bradley E Aouizerat; Annesa Flentje Journal: Psychosom Med Date: 2022-08-16 Impact factor: 3.864
Authors: Wilson Vincent; Adam W Carrico; Samantha E Dilworth; Dietmar Fuchs; Torsten B Neilands; Judith T Moskowitz; Annesa Flentje Journal: J Consult Clin Psychol Date: 2021-03
Authors: Sanjay R Mehta; Jennifer E Iudicello; Jue Lin; Ronald J Ellis; Erin Morgan; Oluwakemi Okwuegbuna; Debra Cookson; Maile Karris; Rowan Saloner; Robert Heaton; Igor Grant; Scott Letendre Journal: Drug Alcohol Depend Date: 2021-02-16 Impact factor: 4.492